Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis
PLOS One · 2025
DOI: 10.1371/journal.pone.0331654 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Hiam Chemaitelly und 21 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. Hauptthemen laut MEDLINE: COVID-19, Cost-Benefit Analysis, COVID-19 Vaccines, Vaccination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weill Cornell Medicine - Qatar, Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine, Qatar Genome Programme and Qatar University Biomedical Research Center.
Abstract (Originalsprache)
Qatar implemented a mass primary-series vaccination campaign to mitigate the impact of the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to retrospectively evaluate the cost-effectiveness of this program both before and after onset of the omicron wave. An economic evaluation was conducted from the public healthcare system perspective between January 5, 2021, and September 18, 2023. Cost-effectiveness was determined using an epidemiological retrospective cohort study and health economic modeling that compared the cohort of individuals who received two vaccine doses with the unvaccinated cohort with respect to incidence of infection, incidence of severe COVID-19 forms, quality-adjusted life years (QALYs), and medical costs. During the pre-omicron phase, primary-series vaccination incurred an additional cost of $104,422,358, led to a gain of 724.7 QALYs, and savings of $54,790,858 in direct medical costs. The incremental cost-effectiveness ratio (ICER) was $68,485 per QALY gained. The number needed to vaccinate was 35.4 individuals (95% CI: 24.4–49.9) to prevent one infection and 718.0 individuals (95% CI: 469.4–984.0) to prevent one severe COVID-19 outcome. The cost per infection averted was $3,180 (95% CI: $2,189-$4,484) and per severe COVID-19 outcome averted was $64,468 (95% CI: $42,146-$88,354). Vaccination of individuals ≥50 years of age, those more clinically vulnerable to severe COVID-19, and those with multiple coexisting conditions was substantially more cost-effective. Cost-effectiveness of primary-series vaccination was substantially reduced during the omicron phase, but vaccination remained cost-effective. Sensitivity analyses confirmed the findings. Primary-series vaccination was cost-effective with an ICER below the 1 GDP per capita threshold during the pre-omicron phase and within the 1–3 GDP per capita thresholds during the omicron phase. Targeted vaccination strategies for those most vulnerable to COVID-19 were the most cost-effective and remained essential, even in situations of moderate vaccine effectiveness or reduced infection severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
- Department of Health Policy, London School of Economics, London, United Kingdom.
- Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, United States of America.
- Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
- Hamad Medical Corporation, Doha, Qatar.
- Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
ORCID-Profile: Hiam Chemaitelly, Houssein H Ayoub, Patrick Tang
Förderung
- Weill Cornell Medicine - Qatar
- Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine
- Qatar Genome Programme and Qatar University Biomedical Research Center
- L'Oreal-UNESCO
- the Qatar Research Development and Innovation Council
Zitieren
APA
Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Hasan, M. R., Yassine, H. M., Al Thani, A. A., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., …, & Abu-Raddad, L. J. (2025). Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis. PLOS One. https://doi.org/10.1371/journal.pone.0331654
Vancouver
Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis. PLOS One. 2025. doi:10.1371/journal.pone.0331654
BibTeX
@article{Chemaitelly2025,
author = {Chemaitelly, Hiam and Ayoub, Houssein H and Coyle, Peter and Tang, Patrick and Hasan, Mohammad R and Yassine, Hadi M and Al Thani, Asmaa A and Al-Kanaani, Zaina and Al-Kuwari, Einas and Jeremijenko, Andrew and Kaleeckal, Anvar Hassan and Latif, Ali Nizar and Shaik, Riyazuddin Mohammad and Abdul-Rahim, Hanan F and Nasrallah, Gheyath K and Al-Kuwari, Mohamed Ghaith and Butt, Adeel A and Al-Romaihi, Hamad Eid and Al-Thani, Mohamed H and Al-Khal, Abdullatif and Bertollini, Roberto and Abu-Raddad, Laith J},
title = {Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0331654}
}
EUVIMED